Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia

Phillip Parente, Howard Gurney, Siobhan Ng, Martina Bahre

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option for patients who have progressed despite docetaxel therapy. Clinical use of cabazitaxel in mCRPC is based on the results of the TROPIC study, which demonstrated an approximately 30% reduction in the risk of death compared with mitoxantrone. In this paper, we draw on accumulating clinical experience with cabazitaxel in Australia to discuss important questions such as how to select the right patient for treatment and how to proactively prevent and manage toxicities associated with this therapy. Recognizing the need for a multidisciplinary approach to patient care, opinion and insight has been sought from medical oncologists, nurses and pharmacists. While lack of trial data means that a number of questions remain unanswered, local clinical experience has helped to guide treatment decisions and refine management protocols. Appropriate patient selection, careful ongoing monitoring and proactive management of adverse events will ensure optimal treatment of patients. Nurses in particular play an important role in educating patients and identifying patients at increased risk of developing adverse events with cabazitaxel. The oncology team must work together to educate patients; taking a proactive approach to issues such as adverse events will help maximize the clinical outcome of cabazitaxel treatment and impact positively on the patient's quality of life.

LanguageEnglish
Pages199-207
Number of pages9
JournalAsia-Pacific Journal of Clinical Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - 1 Sep 2015
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Castration
docetaxel
Nurses
Therapeutics
Mitoxantrone
Patient Rights
Risk Reduction Behavior
cabazitaxel
Pharmacists
Patient Selection
Patient Care
Quality of Life
Health
Oncologists

Keywords

  • Adverse drug event
  • Cancer chemotherapy drug
  • Castration-resistant prostate cancer
  • Drug toxicity
  • Patient safety

Cite this

@article{ba4d511d23b74bfc9682148ab8ecfe94,
title = "Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia",
abstract = "Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option for patients who have progressed despite docetaxel therapy. Clinical use of cabazitaxel in mCRPC is based on the results of the TROPIC study, which demonstrated an approximately 30{\%} reduction in the risk of death compared with mitoxantrone. In this paper, we draw on accumulating clinical experience with cabazitaxel in Australia to discuss important questions such as how to select the right patient for treatment and how to proactively prevent and manage toxicities associated with this therapy. Recognizing the need for a multidisciplinary approach to patient care, opinion and insight has been sought from medical oncologists, nurses and pharmacists. While lack of trial data means that a number of questions remain unanswered, local clinical experience has helped to guide treatment decisions and refine management protocols. Appropriate patient selection, careful ongoing monitoring and proactive management of adverse events will ensure optimal treatment of patients. Nurses in particular play an important role in educating patients and identifying patients at increased risk of developing adverse events with cabazitaxel. The oncology team must work together to educate patients; taking a proactive approach to issues such as adverse events will help maximize the clinical outcome of cabazitaxel treatment and impact positively on the patient's quality of life.",
keywords = "Adverse drug event, Cancer chemotherapy drug, Castration-resistant prostate cancer, Drug toxicity, Patient safety",
author = "Phillip Parente and Howard Gurney and Siobhan Ng and Martina Bahre",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/ajco.12343",
language = "English",
volume = "11",
pages = "199--207",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell, Wiley",
number = "3",

}

Clinical perspectives : Practical insights from clinical experience with cabazitaxel in Australia. / Parente, Phillip; Gurney, Howard; Ng, Siobhan; Bahre, Martina.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 11, No. 3, 01.09.2015, p. 199-207.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Clinical perspectives

T2 - Asia-Pacific Journal of Clinical Oncology

AU - Parente, Phillip

AU - Gurney, Howard

AU - Ng, Siobhan

AU - Bahre, Martina

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option for patients who have progressed despite docetaxel therapy. Clinical use of cabazitaxel in mCRPC is based on the results of the TROPIC study, which demonstrated an approximately 30% reduction in the risk of death compared with mitoxantrone. In this paper, we draw on accumulating clinical experience with cabazitaxel in Australia to discuss important questions such as how to select the right patient for treatment and how to proactively prevent and manage toxicities associated with this therapy. Recognizing the need for a multidisciplinary approach to patient care, opinion and insight has been sought from medical oncologists, nurses and pharmacists. While lack of trial data means that a number of questions remain unanswered, local clinical experience has helped to guide treatment decisions and refine management protocols. Appropriate patient selection, careful ongoing monitoring and proactive management of adverse events will ensure optimal treatment of patients. Nurses in particular play an important role in educating patients and identifying patients at increased risk of developing adverse events with cabazitaxel. The oncology team must work together to educate patients; taking a proactive approach to issues such as adverse events will help maximize the clinical outcome of cabazitaxel treatment and impact positively on the patient's quality of life.

AB - Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option for patients who have progressed despite docetaxel therapy. Clinical use of cabazitaxel in mCRPC is based on the results of the TROPIC study, which demonstrated an approximately 30% reduction in the risk of death compared with mitoxantrone. In this paper, we draw on accumulating clinical experience with cabazitaxel in Australia to discuss important questions such as how to select the right patient for treatment and how to proactively prevent and manage toxicities associated with this therapy. Recognizing the need for a multidisciplinary approach to patient care, opinion and insight has been sought from medical oncologists, nurses and pharmacists. While lack of trial data means that a number of questions remain unanswered, local clinical experience has helped to guide treatment decisions and refine management protocols. Appropriate patient selection, careful ongoing monitoring and proactive management of adverse events will ensure optimal treatment of patients. Nurses in particular play an important role in educating patients and identifying patients at increased risk of developing adverse events with cabazitaxel. The oncology team must work together to educate patients; taking a proactive approach to issues such as adverse events will help maximize the clinical outcome of cabazitaxel treatment and impact positively on the patient's quality of life.

KW - Adverse drug event

KW - Cancer chemotherapy drug

KW - Castration-resistant prostate cancer

KW - Drug toxicity

KW - Patient safety

UR - http://www.scopus.com/inward/record.url?scp=84939259124&partnerID=8YFLogxK

U2 - 10.1111/ajco.12343

DO - 10.1111/ajco.12343

M3 - Review article

VL - 11

SP - 199

EP - 207

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 3

ER -